Abstract
sBackgroundArsenic trioxide (ATO) is reported to be an effective therapeutic agent in acute promyelocytic leukemia (APL) through inducing apoptotic cell death. Buthionine sulfoximine (BSO), an oxidative stress pathway modulator, is suggested as a potential combination therapy for ATO-insensitive leukemia. However, the precise mechanism of BSO-mediated augmentation of ATO-induced apoptosis is not fully understood. In this study we compared the difference in cell death of HL60 leukemia cells treated with ATO/BSO and ATO alone, and investigated the detailed molecular mechanism of BSO-mediated augmentation of ATO-induced cell death.MethodsHL60 APL cells were used for the study. The activation and expression of a series of signal molecules were analyzed with immunoprecipitation and immunoblotting. Apoptotic cell death was detected with caspases and poly (ADP-ribose) polymerase activation. Generation of intracellular reactive oxygen species (ROS) was determined using a redox-sensitive dye. Mitochondrial outer membrane permeabilization was observed with a confocal microscopy using NIR dye and cytochrome c release was determined with immunoblotting. Small interfering (si) RNA was used for inhibition of gene expression.ResultsHL60 cells became more susceptible to ATO in the presence of BSO. ATO/BSO-induced mitochondrial injury was accompanied by reduced mitochondrial outer membrane permeabilization, cytochrome c release and caspase activation. ATO/BSO-induced mitochondrial injury was inhibited by antioxidants. Addition of BSO induced phosphorylation of the pro-apoptotic BCL2 protein, BIMEL, and anti-apoptotic BCL2 protein, MCL1, in treated cells. Phosphorylated BIMEL was dissociated from MCL1 and interacted with BAX, followed by conformational change of BAX. Furthermore, the knockdown of BIMEL with small interfering RNA inhibited the augmentation of ATO-induced apoptosis by BSO.ConclusionsThe enhancing effect of BSO on ATO-induced cell death was characterized at the molecular level for clinical use. Addition of BSO induced mitochondrial injury-mediated apoptosis via the phosphorylation of BIMEL and MCL1, resulting in their dissociation and increased the interaction between BIMEL and BAX.
Highlights
Arsenic trioxide (ATO) is reported to be an effective therapeutic agent in acute promyelocytic leukemia (APL) through inducing apoptotic cell death
We report that the dissociation of BCL2interacting mediator of cell death-extra long protein (BIMEL) and Myeloid cell leukemia-1 protein (MCL1) and the subsequent interaction of BIMEL and B cell lymphoma 2 protein (BCL2)-assocated X protein (BAX) play a critical role in Buthionine sulfoximine (BSO)-mediated augmentation of ATO-induced apoptosis
In the present study, we have demonstrated that BSO augments ATO-induced cell death in HL60 cells and that the augmentation is responsible for reactive oxygen species (ROS)-mediated mitochondrial apoptosis
Summary
Arsenic trioxide (ATO) is reported to be an effective therapeutic agent in acute promyelocytic leukemia (APL) through inducing apoptotic cell death. Arsenic trioxide (ATO) has been reported to be an effective therapeutic agent in both newly diagnosed and relapsed patients with acute promyelocytic leukemia (APL) [1,2] This success has prompted an interest in understanding the molecular mechanisms of action underlying the clinical effectiveness of ATO. Previous studies suggest that the ineffectiveness of ATO in ATO-resistant tumors may be due to low ROS levels, preventing the triggering of effective apoptosis [5,9,10] These early studies provide a rationale for utilizing ATO in combination with oxidative pathway modulators to extend the use of ATO for treating non-APL malignacies. We report that the dissociation of BIMEL and MCL1 and the subsequent interaction of BIMEL and BAX play a critical role in BSO-mediated augmentation of ATO-induced apoptosis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.